Healthcare-focused investment firm OrbiMed has raised over $4.3 billion across three new funds to invest in public and private biotechs amid a lengthy market downturn.

New York-based OrbiMed said in a media release that it raised just more than $1.86 billion for its ninth venture-capital vehicle, OrbiMed Private Investments IX, $1.71 billion for its fourth royalti